Results 61 to 70 of about 17,785 (168)

[18F] PSMA PET‐CT and [18F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests

The Prostate, EarlyView.
ABSTRACT Background To compare choline PET‐CT and PSMA PET‐CT in a cohort of patients with high‐risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results. Methods An observational study was conducted in 116 patients with high‐risk prostate cancer between January ...
M. A. Tárraga‐Honrubia, A. S. Salinas‐Sánchez, S. Navarro‐Jiménez, M. V. Lorenzo‐Sánchez, P. Carrión‐López, J. M. Giménez‐Bachs   +5 more
wiley   +1 more source

Application Analysis of 124I-PPMN for Enhanced Retention in Tumors of Prostate Cancer Xenograft Mice

International Journal of Nanomedicine, 2021
Lei Xia,1,* Li Wen,1,2,* Xiangxi Meng,1 Nina Zhou,1 Xiaoyi Guo,1 Teli Liu,1 Xiaoxia Xu,1 Feng Wang,1 Hua Zhu,1 Zhi Yang1 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for ...
Xia L, Wen L, Meng X, Zhou N, Guo X, Liu T, Xu X, Wang F, Zhu H, Yang Z   +9 more
doaj  

In the Era of mpMRI and PSMA PET/CT: Does Digital Rectal Examination Still Matter?

The Prostate, EarlyView.
ABSTRACT Background With the increasing integration of multiparametric MRI (mpMRI) and 68Ga‐PSMA PET/CT into the diagnostic and staging algorithms of prostate cancer (PCa), digital rectal examination (DRE)—a once foundational and cost‐effective physical examination—has gradually become marginalized in daily clinical practice.
Anil Eker, Fatih Diler, Selda Yilmaz Tatar, Ebru Hasbay, Cagatay Kayar, Berk Karaca, Mahmut Cinar, Yasin Ceylan, Deniz Bolat, Tansu Degirmenci, Serdar Celik   +10 more
wiley   +1 more source

PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease

Clinical and Experimental Gastroenterology, 2023
Mohamed Saleh Ismail,1,* Diane E Peters,2,3,* Steven P Rowe,4,5,* Ali Salavati,6 Sowmya Sharma,1 Robert A Anders,7 Martin Pomper,2,4,5,* Barbara S Slusher,2,3,8,* Florin M Selaru1,5,* 1Division of Gastroenterology, Johns Hopkins ...
Ismail MS, Peters DE, Rowe SP, Salavati A, Sharma S, Anders RA, Pomper M, Slusher BS, Selaru FM   +8 more
doaj  

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, EarlyView.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation

International Journal of Nanomedicine
Wojciech G Lesniak,1 Srikanth Boinapally,1 Gabriela Lofland,1 Zirui Jiang,1 Catherine A Foss,1 Babak Behman Azad,1 Anna Jablonska,1,2 Mauro A Garcia,1 Maria Brzezinski,1 Martin G Pomper1,3 1Russell H.
Lesniak WG, Boinapally S, Lofland G, Jiang Z, Foss CA, Behman Azad B, Jablonska A, Garcia MA, Brzezinski M, Pomper MG   +9 more
doaj  

Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

JCI Insight, 2023
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC).
Erolcan Sayar, Radhika A. Patel, Ilsa M. Coleman, Martine P. Roudier, Ailin Zhang, Pallabi Mustafi, Jin-Yih Low, Brian Hanratty, Lisa S. Ang, Vipul Bhatia, Mohamed Adil, Hasim Bakbak, David A. Quigley, Michael T. Schweizer, Jessica E. Hawley, Lori Kollath, Lawrence D. True, Felix Y. Feng, Neil H. Bander, Eva Corey, John K. Lee, Colm Morrissey, Roman Gulati, Peter S. Nelson, Michael C. Haffner   +24 more
doaj   +1 more source

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source

2D van der Waals System Integrated with Targeting Radio‐Diagnostic and Imaging Functions

Small, EarlyView.
Layered double hydroxide (LDH) nanoplates were engineered for tumor‐targeted imaging and therapy. By exploiting folate receptor (FR) expression levels, the system achieves selective tumor accumulation and high‐resolution dual PET/fluorescence (PET/FL) imaging.
Sairan Eom, Jae Hun Ahn, Jung Yung Kim, Kyo Chul Lee, Yong Jin Lee, Sanoj Rejinold N, Jin‐Ho Choy   +6 more
wiley   +1 more source

Activatable smart contrast agents for photoacoustic imaging

Smart Molecules, EarlyView.
This review highlights recent advances in smart activatable photoacoustic imaging (PAI) contrast agents, which dynamically modulate their optical properties in response to external stimuli or microenvironmental cues. It discusses their molecular design, activation mechanisms, biomedical applications, and future prospects for clinically tailored use ...
Donghyeon Oh, Jihye Lee, Suyoung Park, Juyoung Yoon, Won Jong Kim, Chulhong Kim   +5 more
wiley   +1 more source